指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

重症成人患者基于不同药动学/药效学目标的庆大霉素剂量推荐:一种重新定义的方法

Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach.
指南 / 共识 · Clin Pharmacol · 2023-07-04
一句话结论对于病原体MIC≤1 mg/L的重症成人患者,考虑Cmax/MIC~8-10和AUC24h/MIC≥110双目标,推荐庆大霉素初始剂量8 mg/kg/day(作者结论,需临床验证)。

本研究利用21项已发表研究的重症患者药动学与人口学数据构建一室药动学模型,采用蒙特卡洛模拟评估庆大霉素每日一次给药5-10 mg/kg的疗效达标概率(PTA)及肾毒性风险。结果显示,当MIC<0.5 mg/L时,7 mg/kg/day可使两个疗效目标达标率均超过90%;当MIC升至1 mg/L时,8 mg/kg/day可达到PK/PD及安全目标;对于MIC≥2 mg/L的病原体,所研究的剂量均无法达到疗效目标。作者结论认为,对于MIC≤1 mg/L的病原体,推荐重症患者庆大霉素初始剂量8 mg/kg/day,但强调临床验证至关重要。

要点

  • 对于MIC<0.5 mg/L的病原体,庆大霉素7 mg/kg/day可使Cmax/MIC~8-10和AUC24h/MIC≥110两个疗效目标达标率均超过90%。
  • 当MIC升至1 mg/L时,庆大霉素8 mg/kg/day可达到PK/PD及安全目标。
  • 对于MIC≥2 mg/L的病原体,所研究的庆大霉素剂量(5-10 mg/kg)均不足以达到疗效目标。
  • AUC24h>700 mg·h/L预测肾毒性风险较小,但采用Cmin>2 mg/L目标时肾毒性风险更大。
  • 作者推荐对MIC≤1 mg/L的病原体,重症患者庆大霉素初始剂量为8 mg/kg/day,并强调需临床验证。

适用人群与场景

  • 重症成人患者,感染前3天内
  • 病原体MIC≤1 mg/L时考虑推荐剂量;MIC≥2 mg/L时所研究剂量均不足

诊断标准与关键阈值

  • 疗效PK/PD目标:Cmax/MIC ~8-10 和 AUC24h/MIC ≥110
  • 肾毒性预测阈值:AUC24h >700 mg·h/L 和 Cmin >2 mg/L

处置流程与药物剂量

  • 庆大霉素每日一次给药(ODDG),剂量范围5-10 mg/kg,具体剂量根据MIC选择:MIC<0.5 mg/L时7 mg/kg/day可达两个疗效目标>90%;MIC 1 mg/L时8 mg/kg/day可达PK/PD及安全目标;MIC≥2 mg/L时无 studied 剂量足够。

研究设计与关键结果

  • 研究类型:基于21项已发表研究的药动学与人口学数据构建一室药动学模型,采用蒙特卡洛模拟。
  • 模拟剂量:庆大霉素每日一次5-10 mg/kg。
  • 主要终点:疗效达标概率(PTA)针对Cmax/MIC~8-10和AUC24h/MIC≥110。
  • 结果:MIC<0.5 mg/L时,7 mg/kg/day可使两个疗效目标PTA均>90%;MIC 1 mg/L时,8 mg/kg/day可达PK/PD及安全目标;MIC≥2 mg/L时,所研究剂量均未达到疗效目标。
  • 肾毒性风险:AUC24h>700 mg·h/L预测风险较小,Cmin>2 mg/L目标时风险更大。

证据类型、等级与局限

  • 证据类型:基于文献数据的药动学模型与蒙特卡洛模拟研究。
  • 局限:作者结论强调临床验证至关重要(Clinical validation of our results is essential)。

对床旁实践的改变

  • 作者认为,对于MIC≤1 mg/L的病原体,重症成人患者庆大霉素初始剂量可推荐为8 mg/kg/day(同时考虑Cmax/MIC~8-10和AUC24h/MIC≥110目标),但临床验证至关重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In addition to the maximum plasma concentration (Cmax) to the minimum inhibitory concentration (MIC) ratio, the 24-hour area under the concentration-time curve (AUC24h) to MIC has recently been suggested as pharmacokinetic/pharmacodynamic (PK/PD) targets for efficacy and safety in once-daily dosing of gentamicin (ODDG) in critically ill patients.

PURPOSE: This study aimed to predict the optimal effective dose and risk of nephrotoxicity for gentamicin in critically ill patients for two different PK/PD targets within the first 3 days of infection.

METHODS: The gathered pharmacokinetic and demographic data in critically ill patients from 21 previously published studies were used to build a one-compartment pharmacokinetic model. The Monte Carlo Simulation (MCS) method was conducted with the use of gentamicin once-daily dosing ranging from 5-10 mg/kg. The percentage target attainment (PTA) for efficacy, Cmax/MIC ~8-10 and AUC24h/MIC ≥110 targets, were studied. The AUC24h >700 mg⋅h/L and Cmin >2 mg/L were used to predict the risk of nephrotoxicity.

RESULTS: Gentamicin 7 mg/kg/day could achieve both efficacy targets for more than 90% when the MIC was <0.5 mg/L. When the MIC increased to 1 mg/L, gentamicin 8 mg/kg/day could reach the PK/PD and safety targets. However, for pathogens with MIC ≥2 mg/L, no studied gentamicin doses were sufficient to reach the efficacy target. The risk of nephrotoxicity using AUC24h >700 mg⋅h/L was small, but the risk was greater when applying a Cmin target >2 mg/L.

CONCLUSION: Considering both targets of Cmax/MIC ~8-10 and AUC24h/MIC ≥110, an initial gentamicin dose of 8 mg/kg/day should be recommended in critically ill patients for pathogens with MIC of ≤1 mg/L. Clinical validation of our results is essential.

来源:Clin Pharmacol,查看原文。版权归原作者所有。

参考来源

  1. Abbasi MY, Chaijamorn W, Wiwattanawongsa K, et al. Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach. Clin Pharmacol. 2023. PMID: 37427084. doi:10.2147/CPAA.S417298

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。